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CD4 testing at clinics to assess eligibility for 
Antiretroviral therapy
   Abstract
Background
In 2011, the Ministry of  Health raised the CD4 threshold for 
antiretroviral therapy (ART) eligibility from <250 cells/µl and 
<350 cells/µl, but at the same time only 8.8% of  facilities in Malawi 
with HIV services provided CD4 testing. We conducted a record 
review at 10 rural clinics in Thyolo District to assess the impact of  
introducing CD4 testing on identifying patients eligible for ART.
Methods:
 We abstracted CD4 counts of  all ART-naïve, HIV-infected patients 
with WHO clinical stages 1 and 2 and an initial CD4 test between 
May 2008 and June 2009. At four clinics, we also abstracted CD4 
counts of  patients not initially eligible for ART who were retested 
before April 2010.
Results
Of  1,113 patients tested, the initial CD4 was “≤250 cells/µl” and 
“≤350 cells/µl” in 534 (48.0%). Of  203 patients with follow-up 
results, the most recent CD4 was ≤250 cells/μl in 34 (24.5%), and 
≤350 cells/μl in 64 (46.0%). 
Conclusions
CD4 testing in rural clinics is feasible and identifies many patients 
eligible for ART who would not be identified without CD4 testing. 
CD4 testing needs to be scaled-up to identify patients eligible for 
ART. ART services need to be scaled-up concurrently to meet the 
resulting increased demand.
Introduction
In Malawi, the adult HIV-prevalence was estimated to 
be approximately 12 percent in 2010, with an estimated 
800,000 adults living with HIV.1 Since implementation of  
the national HIV programme in 2004, considerable progress 
has been made towards expanding access to antiretroviral 
therapy (ART) by means of  a policy of  decentralisation and 
increasing the number of  sites that provide ART services. 
During the fourth quarter of  2011, 806 sites provided HIV 
testing and counselling (HTC) services, of  which 241 (29.9%) 
were outside health facilities.2 By the end of  December 2011, 
323,628 patients were alive and on ART provided at 554 
ART sites distributed throughout the country.2
From 2008 to 2011, the Malawi national guidelines 
recommended initiating ART among adolescents and adults 
with World Health Organization (WHO) clinical stage 3 
or 4 HIV disease, and those with a CD4 count ≤250 cells/
μl, regardless of  clinical stage.3 In November 2009, WHO 
released revised guidelines recommending that ART be 
initiated in all HIVinfected adolescents and adults with stage 
3 or 4 disease, or a CD4 count ≤350 cells/μl, regardless 
of  clinical stage.4 In July 2011, the Malawi Ministry of  
Health released new guidelines raising the CD4 threshold 
for ART initiation to ≤350 cells/μl, in line with WHO 
recommendations.5
In Malawi, many HIV-infected persons, particularly those 
living in rural areas, have limited access to HIV services, 
including clinical staging and CD4 testing. At the end of  
2011, only 58 of  the 662 facilities with integrated HIV 
services (8.8%) provided CD4 testing.2 During the fourth 
quarter of  2011, 56 percent of  ART initiations were among 
patients with clinical stage 1 or 2 disease, despite only 58 of  
79 installed CD4 testing devices (73%) being functional.2
Since 2003, Médecins Sans Frontières (MSF) has been 
supporting the Thyolo District Health Office of  the 
Ministry of  Health (MOH) with scaling-up access to ART 
in Thyolo District in the Southern Region of  Malawi. The 
Southern Region had an HIV prevalence of  20.5 percent in 
2007, the most recent year for which figures are available, 
almost double that of  the Central and Northern Regions.1 
In Thyolo District, the expansion and decentralisation of  
HIV services to the primary care level, combined with task 
shifting, has resulted in increased uptake of  HIV care with 
acceptable programme outcomes.6 Starting in 2008, CD4 
testing was introduced in phases in ten clinics that provide 
basic primary health care services. As a result, the number 
of  CD4 tests performed in Thyolo District increased by 38.2 
percent between 2008 and 2011, from 12,386 tests in 2008 
to 17,118 in 2011.
In order to assess the impact of  CD4 testing on the number 
of  patients found to be eligible for ART, we analysed the 
CD4 test results of  ART-naïve patients with HIV infection 
attending clinics in Thyolo District. We also used CD4 test 
results to estimate the impact of  raising the CD4 threshold 
for ART initiation from 250 cells/μl to 350 cells/μl on 
increasing the number of  patients eligible for ART.
Methods 
Setting
We reviewed CD4 test results from ten rural primary health 
care clinics in Thyolo District that provide CD4 testing to 
screen for ART eligibility. The clinics are located in remote 
parts of  Thyolo District, 15 to 65 kilometres from the 
district health laboratory, and are managed by mobile nurses 
who provide clinical services, including HIV care (clinical 
staging, blood draws for CD4 testing, and ART initiation 
and refill), antenatal care and prevention of  mother-to-child 
transmission (PMTCT), family planning, and chronic care 
on set days each month. The clinics are staffed by health 
surveillance assistants (HSAs) who provide HIV testing and 
counselling (HTC) and basic primary health care services on 
a daily basis, and patient support attendants (PSAs). Despite 
decentralisation of  services, many patients still have to travel 
long distances to reach clinics. Poor roads sometimes make 
access to clinics and transport of  specimens to the laboratory 
difficult, particularly during the rainy season.
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Population
The study population comprised HIV-infected, ART-naïve 
patients who attended any of  the ten clinics and required 
CD4 testing to assess their eligibility for ART. We included all 
ART-naïve HIV-infected persons, aged 15 years or older, who 
had an initial CD4 test to screen for ART eligibility between 
May 2008 and June 2009 at any of  the ten clinics offering 
CD4 testing. Patients with clinical stage 3 or 4 disease, and 
children under the age of  15 years, were excluded from the 
analysis.
Procedures
A nurse performed clinical staging and drew blood for 
CD4 testing on designated days. HIV-infected persons with 
clinical stage 3 or 4 disease were referred to the nearest ART 
initiation site without having a CD4 test. Those with clinical 
stage 1 or 2 disease, had blood drawn for CD4 testing. 
Blood samples were transported to the laboratory at Thyolo 
District Hospital by motorbike or in vehicles that visited 
the clinic on the day of  specimen collection. CD4 testing 
was done in the hospital laboratory using a Partec CyFlow® 
counter. Patients were asked to return to the health post for 
their CD4 test result four weeks after the initial visit. Those 
with CD4 counts ≤250 cells/μl were referred to the nearest 
ART initiation site, and those with a CD4 count >250 cells/
μl were given an appointment to return for retesting. CD4 
testing was repeated after 3 months if  the CD4 count was 
between 251 and 350 cells/μl; after 6 months if  the CD4 
count was between 351 and 500 cells/μl; and after 12 months 
if  the CD4 count was >500 cells/μl.
Data collection and analysis
We conducted a retrospective review of  clinic records. We 
abstracted the baseline CD4 test results, age, sex, and the 
initial clinical stage, of  all patients who had a first CD4 test 
during the study period. At four of  the ten clinics, we also 
abstracted the most recent CD4 test results of  patients with 
an initial CD4 count >250 cells/μl (who were not eligible for 
ART in terms of  the eligibility criteria in effect at the time), 
who returned to the clinic for repeat CD4 testing to reassess 
their ART eligibility. The data were entered into a Microsoft 
Excel spreadsheet, and analyzed using Stata version 11 
(StataCorp, College Station, Texas, USA). The Wilcoxon 
rank-sum test was used to assess whether baseline CD4 and 
follow-up CD4 differed significantly according to baseline 
clinical stage.
Ethical considerations
This study was approved by Dr. Likaka, the District Health 
Officer (DHO) of  Thyolo District, and met the criteria for 
an exemption from ethical review7 and the requirement to 
obtain informed consent.8
Results
A total of  1,113 patients were included in the analysis. Their 
age ranged from 15 to 76 years with a median of  35 years. 
The majority of  patients (77.9%) were female. Two hundred 
and ten (18.9%) patients had stage 1 disease; 830 (74.6%) 
had stage 2 disease; and 73 (6.6%) did not have their clinical 
stage recorded. The median initial CD4 count was 360 cells/
μl (Table 1). Among those with a follow-up CD4 test result 
available, the median follow-up CD4 count was 364 cells/
μl. Patients’ initial clinical stage was significantly associated 
with their initial CD4 count (p = 0.0003), but not with their 
most recent follow-up CD4 count (p =0.8678). Of  the 1,113 
patients tested, 323 (29.0%) had an initial CD4 count 250 
cells/μl, and were eligible for ART in terms of  the guidelines 
in effect at the time. An additional 211 (19.0%) had a CD4 
count between 250 cells/μl and 350 cells/μl, making 534 
(48.0%) of  those tested eligible according to the current 
guidelines. Of  203 patients considered in the follow-up 
analysis, 139 (68.5%) had one or more follow-up CD4 test 
results. The median interval between the initial CD4 test 
and the most recent test was 13 months (range: 6 weeks to 
28.7 months). Of  the 139 patients retested, 34 (24.5%) had 
a follow-up CD4 count less than ≤250 cells/μl and were 
eligible for ART in terms of  the guidelines in effect at the 
time. An additional 30 (21.6%), had a CD4 count between 
250 cells/μl and 350 cells/μl, making 64 (46.0%) of  those 
retested eligible according to the current guidelines.
Table 1: Initial and follow up interval according to the initial WHO 
Clinical survey
Table 2. CD4 Counts according to WHO Clinical Stage at the Time 
of  the Initial CD4 Test
Figure 1: Flow Diagram Showing the Number of  Patient Records 
Included in the Record  Review
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Discussion
Our findings demonstrate that CD4 testing is feasible in rural 
settings with limited resources, under routine programme 
conditions. Our findings confirm that CD4 testing of  HIV-
infected patients with clinical stage 1or 2 disease is critical in 
order to determine ART eligibility, and that in the absence 
of  CD4 testing, a substantial portion of  those eligible will 
not be offered ART. Our findings also confirm the value 
of  follow-up CD4 testing for early identification of  patients 
who become eligible for ART after the initial CD4 test. 
Other studies have also found that a substantial proportion 
of  ART-naïve persons with clinical stage 1 and 2 disease 
have low CD4 counts. A study carried out at a demographic 
surveillance site in Malawi, found that assessing ART 
eligibility based on clinical staging alone missed two-thirds 
of  those eligible for ART based on clinical staging and CD4 
count combined.9 A study conducted in Uganda found that 
the sensitivity of  WHO clinical staging to determine.ART 
eligibility was 53.5 percent at a CD4 threshold of  250 cells/
μl, and 49.1 percent at a threshold of  350 cells/μl.10 A study 
conducted at four sites in Ghana found that 29.5 percent of  
patients with clinical stages 1 and 2 disease had a CD4 count 
200 cells/μl.11 
The female preponderance of  patients in our study reflects 
the general female preponderance among people having 
HTC in Malawi: During the last quarter of  2011, 67 percent 
of  people tested for HIV were female, of  whom 48% were 
pregnant.2
In settings where CD4 testing is not available, people tend 
to start ART at an advanced stage of  disease. Late ART 
initiation is associated with poorer health outcomes. A 
previous study conducted in Thyolo District found that there 
was a trend towards increased mortality within 6 months of  
ART initiation with decreasing CD4 count at time of  ART 
initiation.12 A review of  18 cohort studies found that among 
HIV-infected persons with clinical stage 1 or 2 disease 
and a CD4 count of  ≤450 cells/μl, the risk of  developing 
AIDS-defining clinical conditions and the risk of  death 
increased progressively the lower the CD4 count at time 
of  ART initiation.13 A recent review found that mortality 
within the first year after initiating ART was generally higher 
in sub-Saharan African countries than in south-east Asian, 
Caribbean and Latin American countries, primarily due to 
advanced symptomatic HIV disease at the time of  ART 
initiation.14 Another study found that, among patients with 
CD4 counts in the 200 to 500 cells/μl range, the risk of  
developing an AIDS-defining condition was greater before 
than after ART initiation.15 Currently, the availability of  
CD4 testing in Malawi is limited. In order to achieve 100 
percent coverage among those eligible for ART, the limited 
availability of  CD4 testing, especially in remote areas, needs 
to be addressed. In order to improve access to HIV clinical 
services, such services need to be decentralised further, and 
capacity to do clinical staging and CD4 testing needs to be 
expanded. 
The cost of  CD4 testing is the most important constraint: 
A CD4 test costs US $15 (about 3,800 Kwacha at current 
exchange rates). Other major barriers to making CD4 testing 
more widely available include a shortage of  functional 
CD4 testing devices; limited human resources; and a poor 
transport infrastructure, particularly in rural areas. The task 
of  drawing venous blood increases the burden of  work for 
nurses, and laboratories need to have adequate capacity to 
add CD4 testing to the range of  tests available, without 
compromising the availability of  existing services.
These barriers could be addressed by employing and training 
additional laboratory staff  to run and maintain CD4 testing 
devices with the back-up of  a maintenance plan; task-shifting 
of  blood draws from nurses to a lower cadre workers, such as 
health surveillance assistants (with appropriate training and 
supervision); improving transport of  samples to laboratories 
by greater use of  motorbikes; and using technology such 
as SMS to improve the speed with which CD4 results are 
reported to clinics.
In recent years, several POC CD4 testing devices have 
been become commercially available, and have been shown 
to produce results on finger-prick blood specimens with a 
similar level of  accuracy to standard laboratory CD4 assays 
that use venous blood.16-19 In areas without ready access to 
a laboratory, the use of  point-of-care (POC) CD4 testing 
is worth considering as it eliminates many barriers to CD4 
testing. Primary care nurses can be trained to do POC CD4 
testing and to produce results comparable to POC CD4 
tests done by laboratory technicians.17 POC CD4 testing 
enables patients to be given their CD4 test result on the day 
of  testing, thus eliminating the need to return to the clinic 
for CD4 test results and minimising pre-ART loss-to-follow-
up. POC CD4 measuring devices are expensive, however, 
require maintenance, and should only be considered for 
health facilities with a large number of  patients needing 
CD4 testing. We have not introduced POC CD4 testing at 
the clinics included in our study, primarily because of  the 
limited number  of  patients per day needing CD4 testing. 
Our study has some limitations: We do not have information 
on the number of  patients with stage 3 and 4 disease who 
were referred to ART initiation site without CD4 testing, and 
are thus unable to estimate the impact of  CD4 testing on 
increasing the overall number of  people initiating an ART, 
or the impact of  raising the CD4 threshold on the overall 
number of  additional people eligible for ART. We were also 
unable to confirm whether patients returned for their CD4 
test results, and whether those who were referred to an ART 
initiation site were initiated on ART. CD4 testing to screen for 
ART eligibility is only of  value if  those found to be eligible 
are initiated on ART. In the assessment of  follow-up CD4 
test results, we collected only the most recent follow-up CD4 
test result, and are thus unable to assess whether patients 
returned for CD4 testing at the time points recommended in 
the national guidelines.
In order to achieve the full benefit of  CD4 testing, it is 
necessary to ensure that all those who are eligible for ART 
have access to ART. The expansion of  CD4 testing should 
not outpace the ability of  the health system to provide ART 
to those who are eligible. Although the number of  people 
initiated on ART has steadily increased in recent years, ART 
coverage is still lower than targeted.1 As a consequence of  
the implementation of  new national ART guidelines which 
raise the CD4 threshold for ART initiation to 350 cells/μl, 
a large number of  people who were previously ineligible 
for ART, have become eligible. At health posts in Thyolo 
District, increasing the CD4 threshold from 250 cells/μl to 
350 cells/μl has increased the proportion of  people with 
clinical stage 1 and 2 disease eligible for ART by about two 
thirds, placing an additional strain on the health care system. 
There is thus an urgent need to expand ART services as well 
as CD4 testing services.
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